Overview


According to FutureWise analysis the market for Overactive Bladder Treatment in 2023 is US$ 3.63 billion, and is expected to reach US$ 4.9 billion by 2031 at a CAGR of 3.80%.

A medical disorder known as overactive bladder (OAB) is characterized by an uncontrollable contraction of the bladder's muscles, which results in an urgent need to urinate. Urinary urgency (the need to urinate more frequently than usual), and occasional incontinence (leakage of urine prior to using the loo) are common symptoms of OAB. Furthermore, OAB can be caused by various factors, including bladder irritation, nerve damage, and medication side effects. It is a wide-ranging condition that can affect individuals of all age groups, but it is more prevalent in older individuals. Nevertheless, treatments like medications can help with OAB symptom relief.

The market for overactive bladder treatments is growing due to rising trends toward minimally invasive treatments, enormous unmet medical needs, and increased research and development. One of the major elements propelling the expansion of the overactive bladder treatment market is the rise in the world's geriatric population. There is a high likelihood that the geriatric population will experience overactive bladder because they are more likely to acquire chronic conditions, such as neurological dysfunction brought on by aging, which raises the demand for OAB medications. Thus, this boosts the overactive bladder treatment market growth.

FutureWise Market Research has published a report that provides an insightful analysis of overactive bladder treatment market trends that are affecting the overall market growth. This report will provide a detailed analysis of market share, regional insights, and competitor analysis that includes stature of key manufacturers operational in this industry.

According to the analysis conducted by FutureWise research analysts, the overactive bladder treatment market is estimated to register a considerable growth rate over the forecast period. This report lists the market segments and potential prospects available across this industry, in addition providing crucial information on the total valuation currently held by the industry. Moreover, this report will assist key management individuals in an organisation to enhance their decisions pertaining to business expansion as well as strategic changes for increasing customer base.

  • Astellas Pharma Inc.
  • Pfizer, Inc. 
  • Teva Pharmaceutical Industries Limited 
  • Allergan, PLC. 
  • Mylan N.V. 
  • Endo International PLC 
  • Hisamitsu Pharmaceutical Co., Inc.
  • Sanofi
  • Aurobindo Pharma Limited 
  • Johnson & Johnson
  • Intas Pharmaceuticals Ltd. 
  • Apotex Inc. 
  • Macleods Pharmaceuticals Ltd. 
  • Medtronic PLC
  • Cogentix Medical, Inc. 

Recent developments by key players in Overactive Bladder Treatment Market:

  • In July 2022- To treat overactive bladder, Dr. Reddy's Laboratories developed fesoterodine fumarate extended-release pills in the U.S. These tablets are a generic therapeutic version of Pfizer's Toviaz (fesoterodine fumarate) E.R. tablets.

Overactive bladder symptoms include frequent urination, frequent incontinence, and nocturia. Several other medical conditions might also bring on an overactive bladder. The rise in geriatric individuals and the rising prevalence of conditions like Parkinson's disease, which results in an overactive bladder condition, are the main factors propelling the global market. The wellness and welfare of the elderly population are substantially impacted by an overactive bladder since urine incontinence often worsens as people age. As overactive bladder and other urinary disorders become more common, the market for therapies is predicted to grow quickly. The market is projected to experience significant growth owing to upcoming highly effective pharmaceuticals, a robust drug pipeline, and increased awareness campaigns by both public and private organizations that promote early diagnosis of disorders. These factors are anticipated to drive an upward trend in the market's trajectory. Moreover, sacral neuromodulation for OAB is the next-generation implant that is easier to apply, lasts longer and has fewer contraindications. According to a statement released by Axonics, Inc., a manufacturer of novel devices for the treatment of bladder and bowel issues, the company's newly developed, long-lasting, entirely recharge-free sacral neuromodulation (SNM) system, the Axonics F15, was implanted into the first patient in Canada. It is projected that the advancement and innovation in OAB treatment will drive market growth. However, the market for treating overactive bladder is constrained by undesirable pharmaceutical side effects. Constipation, dry mouth, dry or itchy skin, blurred vision, dyspepsia, urinary tract infections, and urinary dysfunction are all common side effects brought on by these medications. In addition, even though many neurostimulators are effective in treating OABs, they can have significant adverse effects in the lab, such as seroma, infection, implant site pain, epidural bleeding, allergic reaction, cerebrospinal fluid (CSF) leakage, paralysis, and skin collapse. Consequently, adverse effects brought on by the drugs hinder the market for overactive bladder treatment.

By Pharmacotherapy

  • Anticholinergics
    • Solifenacin
    • Oxybutynin
    • Darifenacin
    • Fesoterodine
    • Tolterodine
    • Trospium
    • Other Anticholinergics
  • Mirabegron
  • Botox
  • Neurostimulation
  • Intravesical Instillation

By Disease 

  • Idiopathic Overactive Bladder
  • Neurogenic Overactive Bladder
    • Parkinson's Disease
    • Stroke
    • Multiple Sclerosis
    • Spinal Cord Injury
    • Other Disorders

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

This market research report also emphasis on factors affecting the growth rate in various regions listed above. A deep-down analysis of region will also be provided in the final version of this market which is based on conclusion of primary interviews and secondary data point gathered during the process.

By region, the market is segmented into North America, Latin America, Europe, Asia-Pacific, and Middle East & Africa. North America registered the highest share in the market in 2022. This can be attributed to the region's established healthcare sector. The market is anticipated to rise throughout the projected period due to the reimbursement of treatment for overactive bladder, the rising prevalence of the condition with aging populations, and the existence of significant players. In addition, an aging population is anticipated to fuel market expansion. For instance, according to the Statistics Canada 2021 census, there were roughly 7,021,430 individuals who were 65 or older, 3,224,680 of whom were men and 3,796,750 of whom were women. Given that elderly individuals are more susceptible to overactive bladder illness, such a sizable geriatric population in the area is anticipated to promote market expansion.

  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  • Growth prospects
  • SWOT analysis
  • Key market trends
  • Key data-points affecting market growth

  • To provide with an exhaustive analysis on the Overactive Bladder Treatment Market by pharmacotherapy, by disease and by region.
  • To cater comprehensive insights on factors such as drivers, restraints, trends, opportunity, and additionally segmental and regional factors impacting market growth.
  • To evaluate current market trends and forecast micro-markets and the overall market projections which are represented in the format of data-sets and ppt.
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • To provide information on competitors which includes landscape mapping, technological advancements, R&D spending, news concerning strategic alliances, and new product launches

 

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered is free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1. Years Considered for the Study
         3.2. Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1. Secondary Data
          1.1.1. Key Data from Secondary Sources
         1.2. Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Overactive Bladder Treatment Market Variables, Trends and Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Type Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Overactive Bladder Treatment Market Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Overactive Bladder Treatment Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Type Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Type Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Overactive Bladder Treatment Market, By Pharmacotherapy Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Anticholinergics
         1.1. Solifenacin
         1.2. Oxybutynin
         1.3. Fesoterodine
         1.4. Darifenacin
         1.5. Tolterodine
         1.6. Trospium
         1.7. Other Anticholinergics
        2. Mirabegron
        3. Botox
        4. Neurostimulation
        5. Intravesical Instillation

  • 8.   Overactive Bladder Treatment Market, By Disease Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Idiopathic Overactive Bladder
        2. Neurogenic Overactive Bladder
         2.1. Parkinson's Disease
         2.2. Stroke
         2.3. Multiple Sclerosis
         2.4. Spinal Cord Injury
         2.5. Other Disorders

  • 9.   North America Overactive Bladder Treatment Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 10.   Latin America Overactive Bladder Treatment Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 11.   Europe Overactive Bladder Treatment Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 12.   Asia Pacific Overactive Bladder Treatment Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 13.   Middle East and Africa Overactive Bladder Treatment Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 14.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 15.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    •   1. Astellas Pharma Inc.
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. Pfizer, Inc.
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. Teva Pharmaceutical Industries Limited
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. Allergan, PLC.
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. Mylan N.V.
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. Endo International PLC
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. Hisamitsu Pharmaceutical Co., Inc.
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. Sanofi
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. Aurobindo Pharma Limited
         9.1. Company Overview
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
        10.Johnson & Johnson
         10.1. Company Overview
         10.2. Product Portfolio
         10.3. SWOT Analysis
         10.4. Financial Overview
         10.5. Strategic Overview
        11. Intas Pharmaceuticals Ltd.
         11.1. Company Overview
         11.2. Product Portfolio
         11.3. SWOT Analysis
         11.4. Financial Overview
         11.5. Strategic Overview
        12. Apotex Inc.
         12.1. Company Overview
         12.2. Product Portfolio
         12.3. SWOT Analysis
         12.4. Financial Overview
         12.5. Strategic Overview
        13. Macleods Pharmaceuticals Ltd.
         13.1. Company Overview
         13.2. Product Portfolio
         13.3. SWOT Analysis
         13.4. Financial Overview
         13.5. Strategic Overview
        14. Medtronic PLC
         14.1. Company Overview
         14.2. Product Portfolio
         14.3. SWOT Analysis
         14.4. Financial Overview
         14.5. Strategic Overview
        15. Cogentix Medical, Inc.
         15.1. Company Overview
         15.2. Product Portfolio
         15.3. SWOT Analysis
         15.4. Financial Overview
         15.5. Strategic Overview

  • 16.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated by administrations
        5. The overall economic slowdown of the developing and developed nations
  • 17.   FutureWise SME Key Takeaway Points for Client
Partner

Our Clients